GLP1R and prostate carcinoma: Animal studies have also revealed that in prostate cancer, GLP-1 analogs activate the p38 signaling pathway in LNCap cells without affecting the ERK1/2 pathway, thereby suppressing LNCap cell proliferation and inducing apoptosis [54,55,56].